Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted EPS (Basic) of -$0.67 for Q4 2025, down 369.11% on a QoQ basis from -$0.14 in Q3 2025, and down 1277.97% year-over-year from $0.06 in Q4 2024.
Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's EPS (Basic) history runs 2 years deep, the most recent figure standing at -$0.67 for Q4 2025.
- Quarterly EPS (Basic) fell 1277.97% year-over-year to -$0.67 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.12 (down 503.57% YoY) and the FY2025 annual result came in at -$1.33, down 334.93% from the prior year.
- EPS (Basic) was -$0.67 for Q4 2025 at Apimeds Pharmaceuticals US, down from -$0.14 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.04 in Q1 2024 and bottomed at -$0.67 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.32 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.42 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.49 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.32 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.15 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.97 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.11 |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | -0.67 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.67 |
| Sep 30, 2025 | -0.14 |
| Jun 30, 2025 | -0.26 |
| Mar 31, 2025 | -0.05 |
| Dec 31, 2024 | -0.05 |
| Sep 30, 2024 | -0.04 |
| Jun 30, 2024 | -0.06 |
| Mar 31, 2024 | -0.04 |